(.pdf) dr.ssa Antonella Ferro - Progettoeventi

Recommendations

Info

Conclusioni • La malattia HER2 rappresenta un sottotipo prognosticamente sfavorevole • La terapia anti-HER2, in particolare Trastuzumab, ha modificato significativamente l’evoluzione di tale malattia • Altre terapie anti-HER (lapatinib, pertuzumab e T-DM1) hanno contribuito a modificare il processo di cura migliorando la prognosi di tale malattia
Page 1 and 2: Utilizzo dei farmaci nei diversi co
Page 3 and 4: HER2 positive breast cancer “Targ
Page 5 and 6: Trastuzumab (Herceptin) • Il Tras
Page 7 and 8: Trastuzumab binds to ErbB2 on tumou
Page 9 and 10: Antibody-Dependent Cellular Cytotox
Page 11 and 12: Potenziale meccanismo di trastuzuma
Page 13: Malattia adiuvante
Page 17 and 18: DFS: Sequential (Arm B: AC → T
Page 19 and 20: Malattia Neo- adiuvante
Page 21 and 22: Studio NOAH: Event Free Survival ne
Page 23 and 24: Trastuzumab has transformed the pro
Page 25 and 26: Definition of resistance In most tu
Page 27 and 28: Truncated HER2 (p95 HER2 ): clinica
Page 29 and 30: Trastuzumab Capecitabine von Minckw
Page 31 and 32: GBG 26/BIG 03-05: main results Cape
Page 33 and 34: Phase III, randomised, controlled s
Page 35 and 36: Lapatinib • Binds to intracellula
Page 37 and 38: Lapatinib may sensitise HER2 positi
Page 39 and 40: Pertuzumab • Pertuzumab, inibitor
Page 41 and 42: HER2 dimerization is key to signali
Page 43 and 44: Trastuzumab binds to subdomain IV o
Page 45 and 46: Trastuzumab and pertuzumab may have
Page 47: Receptor-T-DM1 complex is internali

(.pdf) dr.ssa Antonella Ferro - Progettoeventi

Create successful ePaper yourself

Delete template?

Save as template?